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between humans, animals, food products, and the environment. 
The differences in host genetics notwithstanding, it is fair to say at 
this point that the genetic basis underlying the varied clinical spec-
trum of disease in non-O157 STEC infections remains unsolved.
The ability to identify the non-O157 STEC that pose a risk to 
the human population using a molecular genetic approach would 
be a boon to clinical medicine where the diagnosis of non-O157 
is challenging at best, or worst, not attempted at all (Bettelheim, 
2007). It would also represent a significant public health achieve-
ment. In fact, almost 15 years ago the World Health Organization 
called the rapid identification of virulent non-O157 STEC a public 
health priority (WHO, 1998), yet few initiatives have occurred since 
the call to advance this agenda.
Mobile eleMents are a source of genetic novelty
Virulence in bacterial pathogens can be attained by acquisition 
of mobile genetic elements such as prophages, transposons, plas-
mids, and genomic islands (Lawrence, 2005). One class of genomic 
island, called pathogenicity islands (PAI), contains virulence genes 
that are involved in host colonization and disease (Dobrindt et al., 
2004). PAIs constitute a flexible gene pool contributing to evolu-
tion and virulence potential and can be used as a genetic signature 
of new and emerging pathogens. In STEC for example, the locus 
of enterocyte effacement (LEE) is a chromosomal PAI encoding 
a type III secretion system (T3SS) necessary for the attaching 
and effacing lesion that is characteristic of disease associated 
with this organism. Notably, the T3SS is a key genetic determi-
nant of both colonization and persistence in animal reservoirs 
and for virulence in humans following zoonotic transmission 
not all stec are created equal
The first outbreak of Shiga toxin-producing Escherichia coli (STEC) 
was recorded in the United States in 1982 (CDC, 1982) and was 
caused by a clone of serotype O157:H7. A retrospective survey of 
older culture collections from before the 1980s indicated that this 
pathogen was a relative newcomer on the scene with a rare preva-
lence (Griffin and Tauxe, 1991). Additional outbreaks of O157:H7 
STEC occurred successively in the UK, continental Europe, Africa, 
and New Zealand over the next decade and outbreaks associated 
with contaminated meat, produce and water became more com-
monplace. In short order, O157:H7 STEC became well-known 
for its ability to cause outbreaks and hemolytic uremic syndrome 
(HUS), a serious infection complication involving acute renal fail-
ure, hemolytic anemic, and thrombocytopenia. With the awareness 
of the clinical significance of O157:H7 STEC came an apprecia-
tion that non-O157 STEC serotypes were variably associated with 
human infections as well (Johnson et al., 2006; Bettelheim, 2007). 
About 150 non-O157 serotypes have now been attributed to spo-
radic and epidemic human infections (Gould et al., 2009), present-
ing with a wildly variable spectrum of disease ranging from watery 
or bloody diarrhea, to HUS and even death. By definition, all of 
these STEC contain at least one Shiga toxin gene (stx), encoding 
the requisite molecule giving rise to HUS complications following 
infection (Karmali et al., 1983). However, while some non-O157 
STEC produce disease symptoms indistinguishable from O157:H7 
infections it is clear that not all non-O157 STEC have the capacity 
to cause HUS, outbreaks, or even any human infections at all. This 
presents a significant dilemma for practitioners of clinical medi-
cine and public health to identify high-risk STEC at the interfaces 
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(Dziva et al., 2004; Coombes, 2009). Given that ruminant ani-
mals are a natural host for STEC, such data provides persuasive 
arguments that the origins of STEC type III secretion might 
have little to do with virulence, but rather its use by modern 
day pathogens as a virulence factor is a convenient upshot of its 
selection in a different ecological setting. Levin (1996) described 
this evolutionary trajectory as “coincidental evolution,” where the 
factors involved in virulence evolved for a purpose other than 
virulence per se. Genetic screens indicate that the substrates of the 
T3SS, called effectors, contribute to persistence in cattle of both 
O157:H7 and non-O157 STEC (Van Diemen et al., 2005), and 
the individual contribution of some of these effector molecules 
in colonization, transmission and virulence has been quantified 
(Wickham et al., 2007; Croxen and Finlay, 2010). Such data high-
light a clinically relevant link between colonization in animals 
and human virulence that is influenced by the repertoire of type 
III secreted substrates in the associated strain. This information 
has important implications for public health because the persist-
ence of type III secretion-competent strains in animal popula-
tions would contemporaneously increase the opportunities for 
zoonotic, foodborne, and environmental transmission of the most 
virulent strains to humans (Coombes, 2009).
Genome sequences of O157:H7 STEC have expanded the 
number of mobile genetic elements well beyond the prototypical 
LEE PAI (Perna et al., 2001). These include many of the O-islands 
(OI) that were originally defined as lineage specific segments 
present in O157:H7 E. coli but absent from non-pathogenic E. coli 
K12. Many of these have origins in bacteriophages that when inte-
grated as prophages into the bacterial chromosome, endowed that 
STEC with new genetic information that could eventually be used 
to modulate colonization and infection biology in humans. The 
individual gene content of some of these O-islands has been linked 
to the epidemic potential and disease severity associated with non-
O157 STEC (Coombes et al., 2008). The precise contribution of all 
mobile genetic elements to STEC virulence and fitness, especially 
non-O157 STEC, is unknown in most cases and a comprehensive 
investigation of virulence determinants has not been undertaken 
for the non-O157 STEC.
Public health PathogenoMics and the concePt of 
seroPathotyPe
Recognizing that the virulence potential of non-O157 STEC was 
likely due to heritable genetic traits, Karmali et al. (2003) estab-
lished a seropathotype classification framework that considers sero-
type association with prior human epidemics, HUS, and diarrhea. 
For example, seropathotype (SPT)-A comprises O157:H7 and 
O157:NM which are the most common causes of outbreaks and 
HUS in most countries; SPT-B strains are also associated with out-
breaks and HUS, but less frequently than SPT-A; SPT-C strains are 
associated with sporadic HUS but not epidemics; SPT-D strains 
are associated with diarrhea but not with outbreaks or HUS, and 
SPT-E comprises multiple STEC serotypes that have never been 
associated with human disease. Although seropathotype mem-
berships are based on real world clinical associations (or absence 
thereof) with disease, the real genetic basis behind the distribution 
of serotypes into a seropathotype category is not known. It can 
be reasonably assumed to be due to the acquisition of virulence 
genes and their continued maintenance as part of the flexible gene 
pool in a strain’s genome, but the genomic landscape of non-O157 
STEC spanning the various SPT classes has not yet been charted 
to address this hypothesis in a comprehensive manner. Although 
informative as an ex post facto determinant of virulence potential, 
the mobile nature of virulence genes exposes a limitation of SPT 
classification as a prognostic indicator of microbial risk. Because 
many virulence genes are acquired by horizontal gene transfer, it 
is possible (and perhaps likely) that STEC that have never been 
associated with human disease (i.e., SPT-E) could acquire mobile 
genetic elements through parallel evolution that convert them into 
a more virulent strain capable of human infections. In this context, 
identifying the genetic complement involved in human infections 
and understanding the complex biology of this host–pathogen 
interaction is a major research goal.
understanding non-o157 stec virulence
The notion of parallel evolution is well-known for pathogenic E. 
coli (Donnenberg and Whittam, 2001; Croxen and Finlay, 2010). 
This idea was put forward over a decade ago (Reid et al., 2000) and 
revisited recently following the first ever sequencing of three non-
O157 STEC associated with human disease, serotypes O26, O111, 
and O103 (Ogura et al., 2009). These seropathotype B strains are 
emerging pathogens with clinical importance in many countries 
as a source of outbreaks and HUS complications following infec-
tion (European Commission, 2007). The genome sequences for 
O26-, O111-, and O103-STEC affirmed that, just as O157:H7 
arose multiple times in a series of genetic steps from a pathogenic 
O55:H7 ancestor (Wick et al., 2005), so too have pathogenic non-
O157 STEC arose from the independent acquisition of mobile 
genetic elements harboring common virulence genes. From what 
common ancestor, if any, these derive from is unknown. In these 
SPT-B strains, the T3SS and associated elements appear to have 
been constructed independently by lambdoid prophages and 
other integrative elements that others have previously shown to 
be involved in the stepwise evolution of O157:H7 (Tobe et al., 
2006; Ogura et al., 2009). The stepwise acquisition of about 30 
known T3SS effectors in STEC, chiefly the horizontally acquired 
non-LEE-encoded nle genes, are particularly interesting when 
considered in the context of selective forces driving their main-
tenance in the genome.
It is known that unlinked effectors can work in concert with one 
another to produce a desired effect on the host cell (Tree et al., 2009; 
Newton et al., 2010), or have functions that oppose host pheno-
types induced by other effectors (Simovitch et al., 2010). A delivery 
order for effectors has also been suggested, with the translocated 
intimin receptor, Tir, sitting atop a delivery hierarchy needed for 
efficient secretion of later type III cargos (Thomas et al., 2007). Also 
implicit is that the positive selection of newly landed effector genes 
would take place in a genetic background already competent for the 
T3SS, since bacteria would presumably find little use for secreted 
cargo without the secretion machinery needed to deliver it. It is 
currently unclear whether there is an acquisition hierarchy for the 
available effector repertoire, or whether T3SS effector genes can be 
maintained for some time under neutral selection in the genome 
of strains lacking effector partners or the core T3SS itself. What 
dictates the “order beneath chaos” (Lawrence and Hendrickson, 
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2005) of STEC genome evolution? How might evolutionary inter-
mediates be selective, and in what environmental or animal niche 
does this selection take place? To get a handle on these questions, 
more sequence information is needed. Sequence information for 
additional non-O157 STEC that span the clinical divide from the 
worst offenders (SPT-B) to the seemingly benign (SPT-E) will be 
the first step in uncovering the provenance of pathogenic behavior 
in this emerging group of bacteria.
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